Page last updated: 2024-12-09
amiridine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
amiridine: do not confuse with neuromedin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 604519 |
CHEMBL ID | 130880 |
CHEBI ID | 125612 |
SCHEMBL ID | 28251 |
MeSH ID | M0142663 |
Synonyms (58)
Synonym |
---|
HMS1685B19 |
HMS3393C11 |
2,3,5,6,7,8-hexahydro-1h-cyclopenta[b]quinolin-9-ylamine |
amiridine |
brn 0475930 |
1h-cyclopenta(b)quinolin-9-amine, 2,3,5,6,7,8-hexahydro- |
9-amino-2,3,5,6,7,8-hexahydro-1h-cyclopenta(b)quinoline |
2,3,5,6,7,8-hexahydro-1h-cyclopenta(b)quinolin-9-amine |
OPREA1_388798 |
OPREA1_177774 |
CBDIVE_008152 |
MLS001423960 |
MLS000758231 |
smr000449322 |
1h-cyclopenta[b]quinolin-9-amine, 2,3,5,6,7,8-hexahydro-, monohydrochloride- [cas] |
ipidacrine |
cpd000449322 |
2,3,5,6,7,8-hexahydro-1h-cyclopenta[b]quinolin-9-amine |
CHEBI:125612 |
HMS2051C11 |
CHEMBL130880 , |
62732-44-9 |
1h,2h,3h,5h,6h,7h,8h-cyclopenta[b]quinolin-9-amine |
F6170-0039 |
bdbm50279987 |
AKOS000663960 |
BBL003609 |
9-amino-2,3,5,6,7,8-hexahydro-1h-cyclopenta[b]quinoline |
STK520619 |
HMS2232L05 |
CCG-100784 |
cv71vtp0vn , |
ipidacrine [inn] |
unii-cv71vtp0vn |
FT-0601640 |
ipidacrine [mi] |
ipidacrine [who-dd] |
ipidacrine [mart.] |
NC00034 |
SCHEMBL28251 |
MB01346 |
DTXSID7048299 |
9-amino-2,3,5,6,7,8-hexahydro-1h-cyclopent[b]quinoline |
1h-cyclopenta(b)quinoline, 2,3,5,6,7,8-hexahydro-9-amino- |
mfcd00618424 |
VU0254176-6 |
1h-cyclopenta[b]quinolin-9-amine, 2,3,5,6,7,8-hexahydro- |
2,3,5,6,7,8-hexahydro-1h-cyclopenta[b]quinoline-9-amine |
9-amino-2,3,5,6,7,8-hexahydro-1h-cyclopenta[b]-quinoline |
DB13668 |
AS-37850 |
Q15409425 |
BRD-K66896231-001-06-5 |
nik(c)\\247 |
CS-0071577 |
HY-W027553 |
EN300-40535 |
Z56766574 |
Research Excerpts
Actions
Excerpt | Reference | Relevance |
---|---|---|
"Amiridine was found to produce a beneficial effect both at the initial and marked stages of the disease." | ( [Effectiveness of amiridin in senile dementia of the Alzheimer type]. Bukatina, EE; Grigor'eva, IV; Sokol'nik, EI, 1991) | 1 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" The dose-response curves for NIK-247 and tacrine were biphasic bell-shaped." | ( Effects of NIK-247 on CO-induced impairment of passive avoidance in mice. Kameyama, T; Kinbara, K; Nabeshima, T; Yoshida, S, 1992) | 0.28 |
" The drug was prescribed in increasing dosages from 10 to 40 mg during 6 months (a dosage of 40 mg was administered from the 4th week of the treatment)." | ( [Neuromidin in the treatment of vascular cognitive disorders]. Golovkova, MS; Iakhno, NN; Lifshits, MIu; Zakharov, VV, 2007) | 0.34 |
" Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of cognitive disorders did not receive the drug." | ( [Neuromidin in mixed vascular and Alzheimer's dementia]. Damulin, IV; Lokshina, AB; Stepkina, DA, 2011) | 0.37 |
" Patients of the first group (n=25) were treated with the general drugs (vasoactive and nootropic preparations, vitamins) as well as with neyromidin in dosage of 15 mg intramuscularly 1 time a day during 10 days." | ( [The сomparative analysis of neyromidin and cerebrolysin effects on neurodynamic processes during craniocerebral injury]. Iurin, AA; Samartsev, IN; Shapkova, EIu; Zhivolupov, SA, 2011) | 0.37 |
" Twenty-five patients received basic therapy and 25 patients were treated with axamon as an add-on drug in dosage of 20 mg 3 times a day during 12 weeks." | ( [Treatment of patients with movement and cognitive disorders in the residual period of stroke]. Agafonov, BV; Dadasheva, MN; Karavashkina, EA; Podrezova, LA; Shevtsova, NN; Smirnova, LA; Vishniakova, TI, 2010) | 0.36 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
aminoquinoline | Any member of the class of quinolines in which the quinoline skeleton is substituted by one or more amino or substituted-amino groups. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (4)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 89.1251 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 19.9526 | 0.0398 | 16.7842 | 39.8107 | AID1454 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Acetylcholinesterase | Electrophorus electricus (electric eel) | IC50 (µMol) | 0.1700 | 0.0000 | 0.9453 | 9.9400 | AID1240487 |
Cholinesterase | Equus caballus (horse) | IC50 (µMol) | 0.0700 | 0.0000 | 2.2214 | 9.4000 | AID1240488 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Bioassays (11)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
AID1240487 | Inhibition of Electrophorus electricus AChE pre-incubated for 5 mins before acetylthiocholine iodide substrate addition by Ellman's method | 2015 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17 | Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening. |
AID1240488 | Inhibition of equine serum BChE pre-incubated for 5 mins before butyrylthiocholineiodide substrate addition by Ellman's method | 2015 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17 | Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening. |
AID1240492 | Inhibition of equine serum BChE at 10 uM pre-incubated for 5 mins before butyrylthiocholineiodide substrate addition by Ellman's method | 2015 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17 | Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening. |
AID1240491 | Inhibition of Electrophorus electricus AChE at 10 uM pre-incubated for 5 mins before acetylthiocholine iodide substrate addition by Ellman's method | 2015 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17 | Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (99)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (5.05) | 18.7374 |
1990's | 41 (41.41) | 18.2507 |
2000's | 10 (10.10) | 29.6817 |
2010's | 37 (37.37) | 24.3611 |
2020's | 6 (6.06) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 19.76
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.76) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 23 (20.18%) | 5.53% |
Reviews | 3 (2.63%) | 6.00% |
Case Studies | 3 (2.63%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 85 (74.56%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |